Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Good efficacy for Sarconeos in DMD
October 2017
SHARING OPTIONS:

PARIS—This year’s World Muscle Society international congress saw Biophytis, a biotechnology company with a focus on developing treatments for age-related diseases, present an abstract titled “Sarconeos demonstrates sharp functional improvement and anti-fibrotic properties in an animal model of Duchenne muscular dystrophy.” Sarconeos is a first-in-class drug candidate developed to treat sarcopenia, an age-related degeneration of skeletal muscle that results in mobility loss. Its mode of action is based on the activation of the MAS receptor, a key facet of the renin-angiotensin system. Duchenne muscular dystrophy (DMD) is a new orphan indication for the drug. In a study, mouse models of DMD treated daily with Sarconeos for eight weeks saw statistically significant improvements in running distances (2.4-fold) compared to untreated mice, as well as a 15-percent improvement in maximal muscle force and a decrease in fibrosis, among other results.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.